Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver dam...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/4291758 |
| _version_ | 1798005139128188928 |
|---|---|
| author | Parisa Shiri Aghbash Hamed Ebrahimzadeh Leylabadlo Hamidreza Fathi Mohaddeseh Bahmani Rojin Chegini Hossein Bannazadeh Baghi |
| author_facet | Parisa Shiri Aghbash Hamed Ebrahimzadeh Leylabadlo Hamidreza Fathi Mohaddeseh Bahmani Rojin Chegini Hossein Bannazadeh Baghi |
| author_sort | Parisa Shiri Aghbash |
| collection | DOAJ |
| description | Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease. |
| first_indexed | 2024-04-11T12:34:23Z |
| format | Article |
| id | doaj.art-5c57645cae8e44569011dae3d57240a8 |
| institution | Directory Open Access Journal |
| issn | 2291-2797 |
| language | English |
| last_indexed | 2024-04-11T12:34:23Z |
| publishDate | 2022-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj.art-5c57645cae8e44569011dae3d57240a82022-12-22T04:23:40ZengHindawi LimitedCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/4291758Hepatic Disorders and COVID-19: From Pathophysiology to Treatment StrategyParisa Shiri Aghbash0Hamed Ebrahimzadeh Leylabadlo1Hamidreza Fathi2Mohaddeseh Bahmani3Rojin Chegini4Hossein Bannazadeh Baghi5Immunology Research CenterLiver and Gastrointestinal Diseases Research CenterDepartment of VirologyDepartment of VirologyMetabolic Liver Disease Research CenterImmunology Research CenterFollowing the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease.http://dx.doi.org/10.1155/2022/4291758 |
| spellingShingle | Parisa Shiri Aghbash Hamed Ebrahimzadeh Leylabadlo Hamidreza Fathi Mohaddeseh Bahmani Rojin Chegini Hossein Bannazadeh Baghi Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy Canadian Journal of Gastroenterology and Hepatology |
| title | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
| title_full | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
| title_fullStr | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
| title_full_unstemmed | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
| title_short | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
| title_sort | hepatic disorders and covid 19 from pathophysiology to treatment strategy |
| url | http://dx.doi.org/10.1155/2022/4291758 |
| work_keys_str_mv | AT parisashiriaghbash hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT hamedebrahimzadehleylabadlo hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT hamidrezafathi hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT mohaddesehbahmani hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT rojinchegini hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT hosseinbannazadehbaghi hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy |